Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Griffin

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Arthritis and Rheumatism|October 31, 2007
Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndromeNdate Fall, Michael Barnes, Sherry Thornton, et al.
Western Journal of Nursing Research|February 15, 2021
Partnering to Increase Colorectal Cancer Screening: Perspectives of Community Advisory Board MembersSusan M Rawl, Sandra Bailey, Beatrice Cork, et al.
Arthritis and Rheumatism|March 1, 2007
The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritisJack Bleesing, Anne Prada, David M Siegel, et al.
The Lancet. Oncology|October 1, 2013
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trialEthan Basch, Karen Autio, Charles J Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2016
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast CancerWeimin Li, Joyce O'Shaughnessy, Daniel Hayes, et al.
Arthritis Care & Research|November 15, 2011
Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conferenceAdam M Huber, Angela B Robinson, Ann M Reed, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 13, 2026
Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+-year results from a multicenter, open-label studyHermine I Brunner, Lyudmila Grebenkina, Irina Nikishina, et al.
The Journal of Rheumatology|August 5, 2025
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III StudyHermine I Brunner, César Pacheco-Tena, Ingrid Louw, et al.
The Journal of Rheumatology|August 1, 2024
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III StudyHermine I Brunner, César Pacheco-Tena, Ingrid Louw, et al.
The New England Journal of Medicine|December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapyCharles J Ryan, Matthew R Smith, Johann S de Bono, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Arthritis and Rheumatism|October 31, 2007
Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndromeNdate Fall, Michael Barnes, Sherry Thornton, et al.
Western Journal of Nursing Research|February 15, 2021
Partnering to Increase Colorectal Cancer Screening: Perspectives of Community Advisory Board MembersSusan M Rawl, Sandra Bailey, Beatrice Cork, et al.
Arthritis and Rheumatism|March 1, 2007
The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritisJack Bleesing, Anne Prada, David M Siegel, et al.
The Lancet. Oncology|October 1, 2013
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trialEthan Basch, Karen Autio, Charles J Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2016
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast CancerWeimin Li, Joyce O'Shaughnessy, Daniel Hayes, et al.
Arthritis Care & Research|November 15, 2011
Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conferenceAdam M Huber, Angela B Robinson, Ann M Reed, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 13, 2026
Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+-year results from a multicenter, open-label studyHermine I Brunner, Lyudmila Grebenkina, Irina Nikishina, et al.
The Journal of Rheumatology|August 5, 2025
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III StudyHermine I Brunner, César Pacheco-Tena, Ingrid Louw, et al.
The Journal of Rheumatology|August 1, 2024
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III StudyHermine I Brunner, César Pacheco-Tena, Ingrid Louw, et al.
The New England Journal of Medicine|December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapyCharles J Ryan, Matthew R Smith, Johann S de Bono, et al.
Pageof 4